Synthes-Stratec Joint Replacement Unit Locks Into Biomet Joint Venture
This article was originally published in The Gray Sheet
Executive Summary
Biomet Merck is looking to expand its 300-person European sales force as part of its acquisition of Synthes-Stratec's European artificial joint replacement business, announced Oct. 29
You may also be interested in...
Synthes Gains Global Marketing Reach, Production Synergy With Mathys Buy
Synthes-Stratec's $1.1 bil. acquisition of Mathys Medical's osteosynthesis business completes the union of the three commercial segments of the AO/ASIF Foundation: Synthes USA, Stratec Holding AG and Mathys Medical Ltd
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.